A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.



O'Neill, PM, Amewu, RK, Charman, SA, Sabbani, S, Gnädig, NF, Straimer, J, Fidock, DA, Shore, ER, Roberts, NL, Wong, MH-L
et al (show 38 more authors) (2017) A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nat Commun, 8. 15159 - ?. ISSN 2041-1723

WarningThere is a more recent version of this item available.
Full text not available from this repository.

Abstract

K13 gene mutations are a primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical utility of artemisinin-based combination therapies, the cornerstone of modern day malaria treatment. Here we describe a multinational drug discovery programme that has delivered a synthetic tetraoxane-based molecule, E209, which meets key requirements of the Medicines for Malaria Venture drug candidate profiles. E209 has potent nanomolar inhibitory activity against multiple strains of P. falciparum and P. vivax in vitro, is efficacious against P. falciparum in in vivo rodent models, produces parasite reduction ratios equivalent to dihydroartemisinin and has pharmacokinetic and pharmacodynamic characteristics compatible with a single-dose cure. In vitro studies with transgenic parasites expressing variant forms of K13 show no cross-resistance with the C580Y mutation, the primary variant observed in Southeast Asia. E209 is a superior next generation endoperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities of artemisinin derivatives.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 01 Jun 2017 09:06
Last Modified: 06 Jun 2017 09:54
DOI: 10.1038/ncomms15159
Open Access URL: https://www.nature.com/articles/ncomms15159
URI: http://livrepository.liverpool.ac.uk/id/eprint/3007767

Available Versions of this Item

Repository Staff Access